{{Infobox drug
| drug_name =
| IUPAC_name = 
| image = 
| width =
| alt = 
| caption =
<!-- Clinical data -->
| pronounce =
| tradename = Strensiq
| Drugs.com = {{drugs.com|parent|strensiq}}
| MedlinePlus = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_US = <!-- A / B / C / D / X / N -->
| pregnancy_category= Insufficient data
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_AU_comment =
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_DE = <!-- Anlage I, II, III -->
| legal_NZ = <!-- Class A, B, C -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_US = Rx-only
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_status = <!-- Free text -->
| routes_of_administration = [[Subcutaneous injection]]
<!-- Pharmacokinetic data -->
| bioavailability = 46–98%
| protein_bound = 
| metabolism = 
| metabolites =
| onset =
| elimination_half-life = 2.3±0.6 days
| duration_of_action =
| excretion = 
<!-- Identifiers -->
| CAS_number = 1174277-80-5
| ATCvet = 
| ATC_prefix = A16
| ATC_suffix = AB13
| PubChem = 
| ChemSpiderID = none
| DrugBank = DB09105
| KEGG = D10595
| UNII = Z633861EIM
<!-- Chemical data -->
| chemical_formula = C<sub>7108</sub>H<sub>11008</sub>N<sub>1968</sub>O<sub>2206</sub>S<sub>56</sub> (protein part)
| molecular_weight = ~160 [[kDa]] (protein part)<br/>~180 kDa (including sugars)
| smiles =
| StdInChI =
| StdInChIKey =
}}
'''Asfotase alfa''' (trade name '''Strensiq''') is a drug used in the treatment of patients with [[perinatal]]/infantile- and juvenile-onset [[hypophosphatasia]].<ref name="Approval">[http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468836.htm FDA approves new treatment for rare metabolic disorder].</ref>

Asfotase alfa is manufactured by [[Alexion Pharmaceuticals]] and It was granted [[breakthrough therapy designation]] by the US [[Food and Drug Administration]] in 2015.<ref>[http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/UCM481542.pdf CDER Breakthrough Therapy Designation Approvals].</ref> It was approved in October 2015 in the US<ref name="Approval" /> and in August 2015 in Europe.<ref>[[European Medicines Agency]]: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003794/human_med_001901.jsp&mid=WC0b01ac058001d124 Strensiq authorisation details].</ref>

==Adverse effects==
The most common adverse effects in studies included injection site reactions (pain, itching, [[erythema]], etc.), headache, limb pain, and [[haematoma]]. Possible rare side effects could not be assessed because of the low number of patients.<ref name="AC">{{cite book|title=Austria-Codex|at=Strensiq Injektionslösung|editor=Haberfeld, H|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2015|language=German}}</ref><ref name="Drugs.com">{{Drugs.com|pro|strensiq}} for Strensiq.</ref>

==Interactions==
Asfotase alfa interferes with [[alkaline phosphatase]] measurements. As asfotase alfa is a [[glycoprotein]] (as opposed to a [[small molecule]]), no relevant interactions via the [[cytochrome P450]] liver enzymes are expected.<ref name="AC" />

==Pharmacology==

===Mechanism of action===
Hypophosphatasia is caused by a genetic defect of [[tissue-nonspecific alkaline phosphatase]] (TNSALP), an enzyme that plays a role in [[bone mineralization]]. Asfotase alfa is a [[Protein production|recombinant]] glycoprotein that contains the [[catalytic domain]] (the active site) of TNSALP. It is thus a form of [[enzyme replacement therapy]].<ref name="AC" /><ref name="Drugs.com" />

===Pharmacokinetics===
After [[subcutaneous injection]], asfotase alfa has a [[bioavailability]] of 46–98% and reaches highest blood plasma concentrations after 24 to 48 hours. [[Elimination half life]] is 2.3±0.6 days on average.<ref name="AC" />

==Chemistry==
The [[peptide]] part of the glycoprotein asfotase alfa consists of two identical chains of 726 [[amino acid]]s each, containing (1) the catalytic domain of TNSALP, (2) the [[Fc region]] of human [[immunoglobulin G1]], and (3) a sequence of ten <small>L</small>-[[aspartate]] residues. The two chains are linked by two [[disulfide bridge]]s. Each chain also contains four internal disulfide bridges.<ref name="AC" /><ref name="Drugs.com" />

The complete peptide sequence of one chain is<ref>DrugBank: [http://www.drugbank.ca/drugs/DB09105 Asfotase Alfa].</ref>
 LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQL
 HHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERS
 RCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEAL
 SQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWK
 SFKPRYKHSHFIWNRTELLTLDPHNVDYLLGLFEPGDMQYELNRNNVTDPSLSEMVVVAI
 QILRKNPKGFFLLVEGGRIDHGHHEGKAKQALHEAVEMDRAIGQAGSLTSSEDTLTVVTA
 DHSHVFTFGGYTPRGNSIFGLAPMLSDTDKKPFTAILYGNGPGYKVVGGERENVSMVDYA
 HNNYQAQSAVPLRHETHGGEDVAVFSKGPMAHLLHGVHEQNYVPHVMAYAACIGANLGHC
 APASSLKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEV
 KFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIE
 KTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
 TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKDIDDDD
 DDDDDD
(the ten "D"s representing the aspartate residues).

Asfotase alfa is produced in [[Chinese hamster ovary cell]]s.<ref name="AC" />

==References==
{{reflist}}

==External links==
* [http://www.strensiq.com/ Official site]

{{Other alimentary tract and metabolism products}}

[[Category:Recombinant proteins]]
[[Category:Hydrolases]]
[[Category:Orphan drugs]]